Parkinson’s drug market set to expand with over 300 late-stage trials currently in progress

Nov. 2, 2011 - PRLog -- According to the report “Parkinson's Disease: World Drug Market 2011-2021” discusses the commercial prospects for the treatment of Parkinson's disease.

The 142 page report shows potential drug revenues to 2021 it informs of opportunities and forecasts with in the industry. It provides revenue predictions for Parkinson's disease treatments at total world, submarket, product and national levels to 2021.

Drugs such as Stalevo/Comtess, Sifrol, Azilect and Requip are analysed to 2021, covering revenues for dopaminergic agents, dopamine agonists, COMT inhibitors, MAO inhibitors and other drugs for Parkinson's disease.The also report discusses Boehringer Ingelheim, Novartis, GSK, Teva and many other companies.

The Parkinson's treatment market has potential to expand. In 2011 there are more than 300 late-stage trials of Parkinson's drugs in progress. The report provides data, analysis and opinion to benefit research, calculations, meetings and presentations.

The report “Parkinson's Disease: World Drug Market 2011-2021” is available from Piribo at:
http://www.pharmaceutical-market-research.com/publication...

Piribo product ID: VIS00329

About Piribo

Piribo http://www.pharmaceutical-market-research.com/publications/diseases_conditions/parkinsons_disease_world_drug_market.html is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer you a current and comprehensive range of specialised intelligence.

# # #

About Piribo.
Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books.